{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "interpro:IPR001759",
      "entity_text" : "PTX",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P01160",
      "entity_text" : "ANF",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Compared to the tumor size in the control mice, the significant difference in tumor growth between the PTX treated mice and PTX + ANF treated mice further confirmed that decreasing the expression or activity of CYP1B1 can potentiate the anticancer abilities of PTX, provided that both treatments are concurrent (P < 0.01).",
  "reading_complete" : "2020-08-02T15:18:47Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T15:17:25Z",
  "trigger" : "potentiate",
  "evidence" : [ "ANF-treated mice further confirmed that decreasing the expression or activity of CYP1B1 can potentiate the anticancer abilities of PTX" ],
  "pmc_id" : "4292762",
  "score" : 0
}